Login to Your Account



Clinic Roundup


Wednesday, July 10, 2013
• Calimmune Inc., of Los Angeles, said the first patient started treatment in a Phase I/II trial testing gene medicine Cal-1. The study will enroll 12 HIV-positive patients who will be infused with their own T cells and stem cells that have been modified to block the HIV receptor CCR5 and prevent HIV fusion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription